2 Firms Guide Amgen's $1.9B Deal For Cancer Drug Biz
Amgen said Thursday it has reached a $1.9 billion deal to buy clinical-stage pharmaceutical group Five Prime Therapeutics and its leading gastric cancer drug candidate in an acquisition guided by Sullivan...To view the full article, register now.
Already a subscriber? Click here to view full article